Made effective March 10, 2025, between NovaBio and HelixPath Research.

NovaBio grants HelixPath a royalty-free, internal-use license for patented biomedical software.

HelixPath commits to a minimum investment of $200,000 per year under this license.

Governing law: State of Massachusetts.

In the event of termination, HelixPath must return all licensed assets and delete derivative works.